New animal models of Alzheimer's disease that display insulin desensitization in the brain

Reviews in the Neurosciences

Volumn 24, Issue 6, 2013, Pages 607-615

  Gao, Chong ^a   Liu, Yueze ^b   Li, Lin ^a   Hölscher, Christian ^a,b  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid ; db db mice; diabetes; exenatide; exendin 4; high fat diet; liraglutide; ob ob mice; streptozocin; tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INSULIN; INSULIN RECEPTOR; LEPTIN RECEPTOR; LIRAGLUTIDE; METFORMIN; PITTSBURGH COMPOUND B; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; AUTOPHAGY; BRAIN CELL; BRAIN CORTEX; CELL PROLIFERATION; COGNITION; COGNITIVE DEFECT; DENTATE GYRUS; DESENSITIZATION; ENVIRONMENTAL FACTOR; EXPLORATORY BEHAVIOR; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIPPOCAMPUS; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEARNING DISORDER; LIPID DIET; MILD COGNITIVE IMPAIRMENT; MOTOR CONTROL; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; SENILE PLAQUE; SIGNAL TRANSDUCTION; SPATIAL LEARNING; SPATIAL MEMORY; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; INSULIN; MICE; NEUROFIBRILLARY TANGLES;

EID: 84889242737     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2013-0034     Document Type: Article

References (90)

1. Agrawal, R., Tyagi, E., Shukla, R., and Nath, C. (2011). Insulin receptor signaling in rat hippocampus: a study in STZ (ICV) induced memory deficit model. Eur. Neuropsychopharmacol. 21, 261-273.
2. Ahren, B., Pacini, G., Foley, J.E., and Schweizer, A. (2005). Improved meal-related ?-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformintreated patients with type 2 diabetes over 1 year. Diabetes Care 28, 1936-1940.
3. Asakawa, A., Inui, A., Inui, T., Katsuura, G., Fujino, M.A., and Kasuga M. (2003). Leptin treatment ameliorates anxiety in ob/ob obese mice. J. Diabetes Complications 17, 105-107.
4. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013). Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123, 2730-2736.
5. Bales, K.R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J.C., Sullivan, P.M., and Paul, S.M. (2009). Human APOE isoform-dependent effects on brain ?-amyloid levels in PDAPP transgenic mice. J. Neurosci. 29, 6771-6779.
6. Banks, A.S., Davis, S.M., Bates, S.H., and Myers M.G., Jr. (2000). Activation of downstream signals by the long form of the leptin receptor. J. Biol. Chem. 275, 14563-14572.
7. Blokland, A. and Jolles J. (1994). Behavioral and biochemical effects of an ICV injection of streptozotocin in old Lewis rats. Pharmacol. Biochem. Behav. 47, 833-837.
8. Buettner, R., Parhofer, K.G., Woenckhaus, M., Wrede, C.E., Kunz-Schughart, L.A., Scholmerich, J., and Bollheimer, L.C. (2006). Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J. Mol. Endocrinol. 36, 485-501.
9. Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999). Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65, 664-670.
10. Carro, E. and Torres-Aleman, I. (2004). Insulin-like growth factor I and Alzheimer's disease, therapeutic prospects? Expert Rev. Neurother. 4, 79-86.
11. Chen, D. and Wang, M.W. (2005). Development and application of rodent models for type 2 diabetes. Diabetes Obes. Metab. 7, 307-317.
12. Chen, Z. and Zhong, C. (2013). Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 108, 21-43.
13. Chen, S., Liu, A.R., An, F.M., Yao, W.B., and Gao X.D. (2012a). Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr). 34, 1211-1224.
14. Chen, Y., Tian, Z., Liang, Z., Sun, S., Dai, C.L., Lee, M.H., LaFerla, F.M., Grundke-Iqbal, I., Iqbal, K., Liu, F., et al. (2012b). Brain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer's disease. PLoS One 7, e51432.
15. Chen, Y., Liang, Z., Blanchard, J., Dai, C.L., Sun, S., Lee, M.H., Grundke-Iqbal, I., Iqbal, K., Liu, F., and Gong C.X. (2013). A non-transgenic mouse model (icv-STZ Mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD Mouse). Mol. Neurobiol. 47, 711-725.
16. Couce, M.E., Burguera, B., Parisi, J.E., Jensen, M.D., and Lloyd R.V. (1997). Localization of leptin receptor in the human brain. Neuroendocrinology 66, 145-150.
17. Craft, S., Baker, L.D., Montine, T.J., Minoshima, S., Watson, G.S., Claxton, A., Arbuckle, M., Callaghan, M., Tsai, E., Plymate S.R., et al. (2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69, 29-38.
18. Crane, P.K., Walker, R., Hubbard, R.A., Li, G., Nathan, D.M., Zheng, H., Haneuse, S., Craft, S., Montine, T.J., Kahn, S.E., et al. (2013). Glucose levels and risk of dementia. N. Engl. J. Med. 369, 540-548.
19. De Felice, F.G. (2013). Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J. Clin. Invest. 123, 531-539.
20. de la Monte, S.M. (2012). Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 9, 35-66.
21. de la Monte, S.M. and Wands, J.R. (2005). Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system, relevance to Alzheimer's disease. J. Alzheimers Dis. 7, 45-61.
22. de Leon, M.J., Ferris, S.H., George, A.E., Christman, D.R., Fowler, J.S., Gentes, C., Reisberg, B., Gee, B., Emmerich, M., Yonekura, Y., et al. (1983). Positron emission tomographic studies of aging and Alzheimer disease. Am. J. Neuroradiol. 4, 568-571.
23. Doherty, G.H., Beccano-Kelly, D., Yan, S.D., Gunn-Moore, F.J., and Harvey, J. (2013). Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid ?. Neurobiol. Aging 34, 226-237.
24. Egefjord, L., Gejl, M., Moller, A., Braendgaard, H., Gottrup, H., Antropova, O., Moller, N., Poulsen, H.E., Gjedde, A., Brock, B., et al. (2012). Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease-protocol for a controlled, randomized double-blinded trial. Dan. Med. J. 59, A4519.
25. Ernst, A., Sharma, A.N., Elased, K.M., Guest, P.C., Rahmoune, H., and Bahn S. (2013). Diabetic db/db mice exhibit central nervous system and peripheral molecular alterations as seen in neurological disorders. Transl. Psychiatry 3, e263.
26. Farr, S.A., Banks, W.A., and Morley, J.E. (2006). Effects of leptin on memory processing. Peptides 27, 1420-1425.
27. Freiherr, J., Hallschmid, M., Frey, W.H., 2nd, Brunner, Y.F., Chapman, C.D., Holscher, C., Craft, S., De Felice, F.G., and Benedict, C. (2013). Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 27, 505-514.
28. Friedland, R.P., Budinger, T.F., Ganz, E., Yano, Y., Mathis, C.A., Koss, B., Ober, B.A., Huesman, R.H., and Derenzo, S.E. (1983). Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F] fluorodeoxyglucose. J. Comput. Assist. Tomogr. 7, 590-598.
29. Friedman, J.M. and Halaas, J.L. (1998). Leptin and the regulation of body weight in mammals. Nature 395, 763-770.
30. Ghilardi, N. and Skoda, R.C. (1997). The leptin receptor activates janus kinase 2 and signals for proliferation in a factordependent cell line. Mol. Endocrinol. 11, 393-399.
31. Greenwood, C.E. and Winocur, G. (1990). Learning and memory impairment in rats fed a high saturated fat diet. Behav. Neural. Biol, 53, 74-87.
32. Hegyi, K., Fulop, K., Kovacs, K., Toth, S., and Falus, A. (2004). Leptin-induced signal transduction pathways. Cell. Biol. Int. 28, 159-169.
33. Hiltunen, M., Khandelwal, V.K., Yaluri, N., Tiilikainen, T., Tusa, M., Koivisto, H., Krzisch, M., Vepsalainen, S., Makinen, P., Kemppainen, S., et al. (2012). Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice. J. Cell. Mol. Med. 16, 1206-1222.
34. Holscher, C. (2011). Diabetes as a risk factor for Alzheimer's disease, insulin signaling impairment in the brain as an alternative model of Alzheimer's disease. Biochem. Soc. Trans. 39, 891-897.
35. Holscher, C. (2012). Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 26, 871-882.
36. Huang, Y. and Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.
37. Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Emond, V., Julien, P., and Calon, F. (2010). High-fat diet aggravates amyloid-β and tau pathologies in the 3xTg-AD mouse model. Neurobiol. Aging. 31, 1516-1531.
38. Kerouz, N.J., Horsch, D., Pons, S., and Kahn, C.R. (1997). Differential regulation of insulin receptor substrates-1 and-2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J. Clin. Invest. 100, 3164-3172.
39. Kim, K.H., Lopez-Casillas, F., Bai, D.H., Luo, X., and Pape, M.E. (1989). Role of reversible phosphorylation of acetyl-CoA carboxylase in long-chain fatty acid synthesis. FASEB. J. 3, 2250-2256.
40. Kim, B., Backus, C., Oh, S., and Feldman, E.L. (2013). Hyperglycemia-induced Tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer's disease. J. Alzheimers Dis. 34, 727-739.
41. Knight, D.S., Mahajan, D.K., and Qiao, X. (2001). Dietary fat up-regulates the apolipoprotein E mRNA level in the Zucker lean rat brain. Neuroreport 12, 3111-3115.
42. Lannert, H. and Hoyer, S. (1998). Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav. Neurosci. 112, 1199-1208.
43. Leibel, R.L. (2008). Molecular physiology of weight regulation in mice and humans. Int. J. Obes. (Lond) 32 Suppl 7, S98-S108.
44. Li, X.L., Aou, S., Oomura, Y., Hori, N., Fukunaga, K., and Hori, T. (2002). Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 113, 607-615.
45. Li, J., Deng, J., Sheng, W., and Zuo, Z. (2012). Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptinresistant mice. Pharmacol. Biochem. Behav. 101, 564-574.
46. Lindstrom, P. (2007). The physiology of obese-hyperglycemic mice [ob/ob mice]. ScientificWorldJournal 7, 666-685.
47. Liu, X.J., Yuan, L., Yang, D., Han, W.N., Li, Q.S., Yang, W., Liu, Q.S., and Qi, J.S. (2013). Melatonin protects against amyloid-?-induced impairments of hippocampal LTP and spatial learning in rats. Synapse 67, 626-636.
48. Luchsinger, J.A., Tang, M.X., Stern, Y., Shea, S., and Mayeux, R. (2001). Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol. 154, 635-641.
49. Marwarha, G. and Ghribi, O. (2012). Leptin signaling and Alzheimer's disease. Am J Neurodegener. Dis. 1, 245-265.
50. Masek, J. and Fabry, P. (1959). High-fat diet and the development of obesity in albino rats. Experientia 15, 444-445.
51. McClean, P.L. and Holscher, C. (2013). Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacol. 76, 57-67.
52. McClean, P.L., Parthsarathy, V., Faivre, E., and Holscher, C. (2011). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31, 6587-6594.
53. McNeilly, A.D., Williamson, R., Balfour, D.J., Stewart, C.A., and Sutherland, C. (2012). A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin. Diabetologia 55, 3061-3070.
54. Mercer, J.G., Hoggard, N., Williams, L.M., Lawrence, C.B., Hannah, L.T., and Trayhurn, P. (1996). Localization of leptin receptor mRNA and the long form splice variant (Ob-Rb) in mouse hypothalamus and adjacent brain regions by in situ hybridization. FEBS Lett. 387, 113-116.
55. Minoshima, S., Giordani, B., Berent, S., Frey, K.A., Foster, N.L., and Kuhl, D.E. (1997). Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42, 85-94.
56. Moloney, A.M., Griffin, R.J., Timmons, S., O'Connor, R., Ravid, R., and O'Neill, C. (2010). Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31, 224-243.
57. Mosconi, L. (2005). Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32, 486-510.
58. Murray-Lyon, I.M., Eddleston, A.L., Williams, R., Brown, M., Hogbin, B.M., Bennett, A., Edwards, J.C., and Taylor, K.W. (1968). Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 2, 895-898.
59. Oomura, Y., Hori, N., Shiraishi, T., Fukunaga, K., Takeda, H., Tsuji, M., Matsumiya, T., Ishibashi, M., Aou, S., Li, X.L., et al. (2006). Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides 27, 2738-2749.
60. Parthsarathy, V. and Holscher, C. (2013). Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PloS One 8, e58784.
61. Patil, S. and Chan, C. (2005). Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons. Neurosci. Lett. 384, 288-293.
62. Pedrini, S., Thomas, C., Brautigam, H., Schmeidler, J., Ho, L., Fraser, P., Westaway, D., Hyslop, P.S., Martins, R.N., Buxbaum, J.D., et al. (2009). Dietary composition modulates brain mass and solubilizable Aβlevels in a mouse model of aggressive Alzheimer's amyloid pathology. Mol. Neurodegener. 4, 40-49.
63. Porter, W.D., Flatt, P.R., Holscher, C., and Gault, V.A. (2013). Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice. Int. J. Obes. (Lond). 37, 678-684.
64. Pouryamout, L., Dams, J., Wasem, J., Dodel, R., and Neumann, A. (2012). Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. Drugs 72, 789-802.
65. Reger, M.A., Watson, G.S., Frey, W.H., 2nd, Baker, L.D., Cholerton, B., Keeling, M.L., Belongia, D.A., Fishel, M.A., Plymate, S.R., Schellenberg, G.D., et al. (2006). Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging 27, 451-458.
66. Reger, M.A., Watson, G.S., Green, P.S., Baker, L.D., Cholerton, B., Fishel, M.A., Plymate, S.R., Cherrier, M.M., Schellenberg, G.D., Frey, W.H., 2nd, et al. (2008). Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-β in memory-impaired older adults. J. Alzheimers Dis. 13, 323-331.
67. Salkovic-Petrisic, M. and Hoyer, S. (2007). Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J. Neural. Transm. Suppl. 72, 217-233.
68. Salkovic-Petrisic, M., Knezovic, A., Hoyer, S., and Riederer, P. (2013). What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J. Neural. Transm. 120, 233-252.
69. Saxena, G., Patro, I.K., and Nath, C. (2011). ICV STZ induced impairment in memory and neuronal mitochondrial function: a protective role of nicotinic receptor. Behav. Brain. Res. 224, 50-57.
70. Schioth, H.B., Craft, S., Brooks, S.J., Frey, W.H., 2nd, and Benedict, C. (2012). Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol Neurobiol. 46, 4-10.
71. Schnedl, W.J., Ferber, S., Johnson, J.H., and Newgard, C.B. (1994). STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 43, 1326-1333.
72. Schraml, F., Chen, K., Ayutyanont, N., Auttawut, R., Langbaum, J.B., Lee, W., Liu, X., Bandy, D., Reeder, S.Q., Alexander, G.E., et al. (2013). Association between an Alzheimer's Disease-Related Index and Gene Dose. PLoS One 8, e67163.
73. Schrijvers, E.M., Witteman, J.C., Sijbrands, E.J., Hofman, A., Koudstaal, P.J., and Breteler, M.M. (2010). Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 75, 1982-1987.
74. Selkoe, D.J. (2000). Toward a comprehensive theory for Alzheimer's disease. Hypothesis, Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid ?-protein. Ann. N.Y. Acad. Sci. 924, 17-25.
75. Serbedzija, P. and Ishii, D.N. (2012). Insulin and insulin-like growth factor prevent brain atrophy and cognitive impairment in diabetic rats. Indian. J. Endocrinol. Metab. 16, S601-S610.
76. Shingo, A.S., Kanabayashi, T., Murase T., and Kito, S. (2012). Cognitive decline in STZ-3V rats is largely due to dysfunctional insulin signaling through the dentate gyrus. Behav. Brain. Res. 229, 378-383.
77. Shingo, A.S., Kanabayashi, T., Kito, S., and Murase, T. (2013). Intracerebroventricular administration of an insulin analogue recovers STZ-induced cognitive decline in rats. Behav. Brain. Res. 241, 105-111.
78. Shonesy, B.C., Thiruchelvam, K., Parameshwaran, K., Rahman, E.A., Karuppagounder, S.S., Huggins, K.W., Pinkert, C.A., Amin, R., Dhanasekaran, M., Suppiramaniam, V. (2012). Central insulin resistance and synaptic dysfunction in intracerebroventricularstreptozotocin injected rodents. Neurobiol. Aging. 33, 430. e5-e18.
79. Singh, S., Kushwah, A.S., Singh, R., Farswan, M., and Kaur, R. (2012). Current therapeutic strategy in Alzheimer's disease. Eur. Rev. Med. Pharmacol. Sci. 16, 1651-1664.
80. Steen, E., Terry, B.M., Rivera, E.J., Cannon, J.L., Neely, T.R., Tavares, R., Xu, X.J., Wands, J.R., and de la Monte, S.M. (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J. Alzheimers. Dis. 7, 63-80.
81. Strachan, M.W. (2005). Insulin and cognitive function in humans, experimental data and therapeutic considerations. Biochem. Soc. Trans. 33, 1037-1040.
82. Szkudelski, T. (2001). The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 50, 537-546.
83. Takeda, S., Sato, N., Uchio-Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D., Kurinami, H., Shinohara, M., Rakugi, H., and Morishita, R. (2010). Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβdeposition in an Alzheimer mouse model with diabetes. Proc. Natl. Acad. Sci. USA 107, 7036-7041.
84. Talbot, K., Wang, H.Y., Kazi, H., Han, L.Y., Bakshi, K.P., Stucky, A., Fuino, R.L., Kawaguchi, K.R., Samoyedny, A.J., Wilson, R.S., et al. (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122, 1316-1338.
85. van den Brink, G.R., O'Toole, T., Hardwick, J.C., van den Boogaardt, D.E., Versteeg, H.H., van Deventer, S.J., and Peppelenbosch, M.P. (2000). Leptin signaling in human peripheral blood mononuclear cells, activation of p38 and p42/44 mitogen-activated protein (MAP) kinase and p70 S6 kinase. Mol. Cell. Biol. Res. Commun. 4, 144-150.
86. Vignini, A., Giulietti, A., Nanetti, L., Raffaelli, F., Giusti, L., Mazzanti, L., and Provinciali, L. (2013). Alzheimer's disease and diabetes: new insights and unifying therapies. Curr. Diabetes. Rev. 9, 218-227.
87. Wang, Z. and Gleichmann, H. (1998). GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes 47, 50-56.
88. Wang, X., Zheng, W., Xie, J.W., Wang, T., Wang, S.L., Teng, W.P., and Wang, Z.Y. (2010). Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol. Neurodegener. 5, 46-54.
89. Winzell, M.S. and Ahren, B. (2004). The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53 Suppl 3, S215-S219.
90. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J.M. (1994). Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432.